Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28861
Title: Differential Effects of APOE and Modifiable Risk Factors on Hippocampal Volume Loss and Memory Decline in AB- and AB+ Older Adults.
Austin Authors: Rosenich, Emily;Bransby, Lisa;Yassi, Nawaf;Fripp, Jurgen;Laws, Simon M;Martins, Ralph N;Fowler, Christopher;Rainey-Smith, Stephanie R;Rowe, Christopher C ;Masters, Colin L ;Maruff, Paul;Lim, Yen Ying
Affiliation: Medicine (University of Melbourne)
CSIRO Health and Biosecurity, Australian e-Health Research Centre, Brisbane, QLD, Australia..
Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, WA, Australia..
The Florey Institute of Neuroscience and Mental Health
Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC, Australia..
Cogstate Ltd., Melbourne, VIC, Australia..
Departments of Medicine and Neurology, Melbourne Brain Centre at The Royal Melbourne Hospital, University of Melbourne, Parkville, VIC, Australia..
Population Health and Immunity Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, Australia..
Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia..
School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia..
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia..
Australian Alzheimer's Research Foundation, Sarich Neuroscience Research Institute, Nedlands, WA, Australia..
Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg..
Issue Date: 26-Apr-2022
Date: 2022-02-15
Publication information: Neurology 2022; 98(17): e1704-e1715
Abstract: This prospective study sought to determine the association of modifiable/non-modifiable components included in the Cardiovascular Risk Factors, Aging, and Incidence of Dementia (CAIDE) risk score with hippocampal volume (HV) loss and episodic memory (EM) decline in cognitively normal (CN) older adults classified as brain β-amyloid negative (Aβ-) or Aβ+. Australian Imaging, Biomarkers and Lifestyle study participants (aged 58-91) who completed ≥2 neuropsychological assessments and a brain Aβ PET scan (N=592) were included in this study. We computed the CAIDE risk score (age, sex, Apolipoprotein E (APOE) ε4 status, education, hypertension, body mass index (BMI), hypercholesterinemia, physical inactivity) and a modifiable CAIDE risk score (CAIDE-MR; education, hypertension, BMI, hypercholesterinemia, physical inactivity) for each participant. Aβ+ was classified using a Centiloid >25. Linear mixed models assessed interactions between each CAIDE score, Aβ group and time on HV loss and EM decline. Age, sex and APOE ε4 were included as separate predictors in CAIDE-MR models to assess differential associations. Exploratory analyses examined relationships between individual modifiable risk factors and outcomes in Aβ- CN adults. We observed a significant Aβ group × CAIDE × time interaction on HV loss (β(SE)=-0.04(0.01); p<.000) but not EM decline (β(SE)=-2.33(9.96); p=.98). Decomposition revealed a significant CAIDE × time interaction in Aβ+ participants only. When modifiable/non-modifiable CAIDE components were considered separately, we observed a significant Aβ group × CAIDE-MR × time interaction on EM decline only (β(SE)=3.03(1.18); p=.01). A significant CAIDE-MR score × time interaction was observed in Aβ- participants only. Significant interactions between APOE ε4 and age × time on HV loss and EM decline were observed in both groups. Exploratory analyses in Aβ- CN participants revealed a significant interaction between BMI × time on EM decline (β(SE)=-3.30(1.43); p=.02). These results are consistent with studies showing that increasing age and APOE ε4 are associated with increased rates of HV loss and EM decline. In Aβ- CNs, lower prevalence of modifiable cardiovascular risk factors was associated with less HV loss and EM decline over ∼10 years, suggesting interventions to reduce modifiable cardiovascular risk factors could be beneficial in this group.
URI: https://ahro.austin.org.au/austinjspui/handle/1/28861
DOI: 10.1212/WNL.0000000000200118
ORCID: https://orcid.org/0000-0002-7600-9277
https://orcid.org/0000-0002-2846-6895
https://orcid.org/0000-0002-0685-0060
https://orcid.org/0000-0001-9705-0079
https://orcid.org/0000-0002-4355-7082
https://orcid.org/0000-0002-4828-9363
https://orcid.org/0000-0003-1397-0359
https://orcid.org/0000-0003-3910-2453
https://orcid.org/0000-0003-3072-7940
https://orcid.org/0000-0002-6947-9537
https://orcid.org/0000-0002-0308-5156
Journal: Neurology
PubMed URL: 35169009
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35169009/
Type: Journal Article
Appears in Collections:Journal articles

Show full item record

Page view(s)

26
checked on Apr 17, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.